<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Monitoring</title>
    <description></description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>​Oura rings in $900M fundraising round for global expansion</title>
      <description>Oura Health Oy raised more than $900 million in a series E funding round to fuel global expansion of its popular smart ring and development of new health technologies. The new infusion brings the company’s total funds raised to date to $1.5 billion and implies a corporate valuation of about $11 billion, Oura said.</description>
      <content:encoded>
        <![CDATA[Oura Health Oy raised more than $900 million in a series E funding round to fuel global expansion of its popular smart ring and development of new health technologies. The new infusion brings the company’s total funds raised to date to $1.5 billion and implies a corporate valuation of about $11 billion, Oura said.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/724916</guid>
      <pubDate>Tue, 14 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724916-oura-rings-in-900m-fundraising-round-for-global-expansion</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Oura-Ring-19dec24.webp?t=1760478501" type="image/jpeg" medium="image" fileSize="394173">
        <media:title type="plain">Oura Ring</media:title>
        <media:description type="plain">Oura ring. Credit: Oura Health Oy</media:description>
      </media:content>
    </item>
    <item>
      <title>Neurothread biosignal monitoring could sew up neurological diagnoses</title>
      <description>Researchers from The Ohio State University have filed for protection of Neurothread, a wire-type neurotransmitter-sensing platform that utilizes the cross-section of commercially available ultrathin microwires as microelectrodes.</description>
      <content:encoded>
        <![CDATA[Researchers from The Ohio State University have filed for protection of Neurothread, a wire-type neurotransmitter-sensing platform that utilizes the cross-section of commercially available ultrathin microwires as microelectrodes.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/717996</guid>
      <pubDate>Thu, 20 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717996-neurothread-biosignal-monitoring-could-sew-up-neurological-diagnoses</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/WO2025049953-A1-Conductive-microwire-based-biochemical-sensors-for-real-time-neurological-monitoring.-3-20.webp?t=1742504272" type="image/jpeg" medium="image" fileSize="185242">
        <media:title type="plain">WO2025049953-A1, “Conductive microwire-based biochemical sensors for real-time neurological monitoring.”</media:title>
        <media:description type="plain">WO2025049953-A1, “Conductive microwire-based biochemical sensors for real-time neurological monitoring.”Assignee: Ohio State Innovation FoundationInventors: Li, Jinghua; Liu, Tzu-LiIPC codes: A61B 5/1468; C12Q 1/58; G01N 33/94; G01N 27/327; C12Q 1/26; C12Q 1/54Publication date: Mar. 6, 2025Earliest priority details: US2023535687, Aug. 31, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>EEG earpiece predicts seizures up to an hour before onset</title>
      <description>The first patenting from Theta Neurotech Inc. sees the company’s co-founders describe their development of a wearable earpiece that uses an electroencephalography technology and machine learning algorithms to alert epilepsy patients 30 to 60 minutes before they have a seizure.</description>
      <content:encoded>
        <![CDATA[The first patenting from Theta Neurotech Inc. sees the company’s co-founders describe their development of a wearable earpiece that uses an electroencephalography technology and machine learning algorithms to alert epilepsy patients 30 to 60 minutes before they have a seizure.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/717168</guid>
      <pubDate>Thu, 20 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717168-eeg-earpiece-predicts-seizures-up-to-an-hour-before-onset</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/EEG-earpiece-20feb25.webp?t=1740093036" type="image/jpeg" medium="image" fileSize="230890">
        <media:title type="plain">EEG earpiece</media:title>
        <media:description type="plain">WO2025030028-A1, “Wearable device for measurement of brain activity.”Assignee: Theta NeurotechInventors: Pierson, Truman; Hussain, Ali; Fitz, ChristopherIPC codes: A61B 5/00; A61B 5/291; A61B 5/259Publication date: Feb. 6, 2025 (also published as US20250040867-A1)Earliest priority details: US2023229340, Aug. 2, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Northwestern is harnessing AI for real-time MRI safety assessment</title>
      <description>A recent patent application from Laleh Rad, associate professor of Biomedical Engineering and Radiology at Northwestern University, describes the use of machine learning for real-time risk assessment of magnetic resonance imaging in patients with conductive implants for whom tissue heating from radiofrequency excitation fields remains a major concern.</description>
      <content:encoded>
        <![CDATA[A recent patent application from Laleh Rad, associate professor of Biomedical Engineering and Radiology at Northwestern University, describes the use of machine learning for real-time risk assessment of magnetic resonance imaging in patients with conductive implants for whom tissue heating from radiofrequency excitation fields remains a major concern.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/716914</guid>
      <pubDate>Wed, 12 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716914-northwestern-is-harnessing-ai-for-real-time-mri-safety-assessment</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/mri-safety-12feb25.webp?t=1739396434" type="image/jpeg" medium="image" fileSize="305973">
        <media:title type="plain">mri-safety</media:title>
        <media:description type="plain">US20250029246-A1, “Method and system to predict radiofrequency heating of medical implants.”Assignee: Northwestern UniversityInventors: Golestani Rad, LalehIPC codes: A61N 1/05; G06T 7/00Publication date: Jan. 23, 2025Earliest priority details: US2023528202, July 21, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Bioresorbable microelectrode array implant for cardiac conditions</title>
      <description>Researchers from The George Washington University and Northwestern University filed for protection of a bioresorbable, transparent, microelectrode array (MEA) technology that they believe offers unique advantages.</description>
      <content:encoded>
        <![CDATA[  Researchers from The George Washington University and Northwestern University filed for protection of a bioresorbable, transparent, microelectrode array (MEA) technology that they believe offers unique advantages.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/715952</guid>
      <pubDate>Fri, 10 Jan 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715952-bioresorbable-microelectrode-array-implant-for-cardiac-conditions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/soft-microelectrode-10jan25.webp?t=1736546181" type="image/jpeg" medium="image" fileSize="151871">
        <media:title type="plain">soft microelectrode</media:title>
        <media:description type="plain">WO2025007130-A2, “Soft, bioresorbable, transparent microelectrode array for cardiac applications.”Assignee: The George Washington UniversityInventors: Lu, Luyao; Efimov, Igor R.IPC Codes: A61N 5/06Publication date: Jan. 2, 2025Earliest priority details: US2023524485, June 30, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>NC State researchers file patent for wound monitoring sensors</title>
      <description>Researchers from North Carolina State University filed for protection of miniaturized, wireless, wound-monitoring sensors that may be incorporated into swabs or wound dressings for real-time, accurate assessment of wound status.</description>
      <content:encoded>
        <![CDATA[  Researchers from North Carolina State University filed for protection of miniaturized, wireless, wound-monitoring sensors that may be incorporated into swabs or wound dressings for real-time, accurate assessment of wound status.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/714264</guid>
      <pubDate>Tue, 19 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714264-nc-state-researchers-file-patent-for-wound-monitoring-sensors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/wound-monitoring-19nov24.webp?t=1732054933" type="image/jpeg" medium="image" fileSize="628223">
        <media:title type="plain">wound monitoring</media:title>
        <media:description type="plain">US20240366146-A1, “Swab-integrated multi-analyte sensors for wound monitoring.”Assignee: North Carolina State UniversityInventors: Bandodkar, Amay; Kim, Yong JaeIPC codes: A61B 5/103; A61B 5/00Publication date: Nov. 7, 2024Earliest priority details: US2023464378, May 5, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Identifyher patents wearable perimenopause tracking sensor</title>
      <description>The first filing to emerge from Identifyher Ltd. seeks to gain protection for a wearable sensor that women can wear daily to track potential symptoms of perimenopause, providing them with data that can be used to find the right management plan for their needs.</description>
      <content:encoded>
        <![CDATA[The first filing to emerge from Identifyher Ltd. seeks to gain protection for a wearable sensor that women can wear daily to track potential symptoms of perimenopause, providing them with data that can be used to find the right management plan for their needs.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/714256</guid>
      <pubDate>Mon, 18 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714256-identifyher-patents-wearable-perimenopause-tracking-sensor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/perimenopause-wearable-sensor-18nov24.webp?t=1731966910" type="image/jpeg" medium="image" fileSize="102245">
        <media:title type="plain">perimenopause wearable sensor</media:title>
        <media:description type="plain">EP4459634-A1, “Computer implemented method, computer system and computer program product for determining a menopausal state.”Assignee: Identifyher Ltd.Inventors: O'Gorman, Donal; Kerr, Alish; Davis, HeidiIPC codes: G16H 50/20; G16H 50/00Publication date: Nov. 6, 2024 (also published as US20240366192-A1, Nov. 7, 2024)Earliest priority details: EP2023171642, May 4, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Fibra patents smart underwear for monitoring fertility</title>
      <description>The first patenting from Fibra Inc. sees its founder and CEO Parnian Majid describe their development of a non-invasive wearable device which tracks fertility data through the measurement of various physiological parameters.</description>
      <content:encoded>
        <![CDATA[The first patenting from Fibra Inc. sees its founder and CEO Parnian Majid describe their development of a non-invasive wearable device which tracks fertility data through the measurement of various physiological parameters.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/713853</guid>
      <pubDate>Thu, 07 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/713853-fibra-patents-smart-underwear-for-monitoring-fertility</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/biomonitoring-underwear-7nov24.webp?t=1731019084" type="image/jpeg" medium="image" fileSize="156418">
        <media:title type="plain">biomonitoring fertility-tracking underwear</media:title>
        <media:description type="plain">WO2024218610-A1, “Extrusion-printed biochemical sensor, wearable device, and system for determining reproductive status of user.”Assignee: Fibra Inc.Inventors: Majd, ParnianIPC codes: A61B 5/00; G01N 27/06; A61B 10/00; G01N 27/00; G01K 13/20Publication date: Oct. 24, 2024Earliest priority details: US2023460361, April 19, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Wearable acoustic patch developed for transdermal drug delivery</title>
      <description>A team of researchers from the University of Northumbria filed for protection of a flexible transdermal patch taht uses surface acoustic wave technology they believe offers distinct advantages over traditional transdermal patches.</description>
      <content:encoded>
        <![CDATA[A team of researchers from the University of Northumbria filed for protection of a flexible transdermal patch taht uses surface acoustic wave  technology they believe offers distinct advantages over traditional transdermal patches.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/710423</guid>
      <pubDate>Tue, 23 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710423-wearable-acoustic-patch-developed-for-transdermal-drug-delivery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/transdermal-patent-23july24.webp?t=1721769684" type="image/jpeg" medium="image" fileSize="90424">
        <media:title type="plain">transdermal patch</media:title>
        <media:description type="plain">WO2024126989-A1, “Patch.”Assignee: University of Northumbria at NewcastleInventors: Arnold, Peter; Fu, Richard; Torun, HamdiIPC Codes: A61N 7/00; A61M 5/142; A61M 37/00Publication Date: June 20, 2024Earliest priority details: GB202218636, Dec. 12, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>USC team develops minimally invasive neural recording, stimulation system</title>
      <description>Researchers from the University of Southern California filed for protection of a thin film electrode array they developed to be implanted using endovascular methods for minimally invasive, high-resolution electrical recording and stimulation of the nervous system and other electrogenic tissue.</description>
      <content:encoded>
        <![CDATA[Researchers from the University of Southern California filed for protection of a thin film electrode array they developed to be implanted using endovascular methods for minimally invasive, high-resolution electrical recording and stimulation of the nervous system and other electrogenic tissue.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/710314</guid>
      <pubDate>Thu, 18 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710314-usc-team-develops-minimally-invasive-neural-recording-stimulation-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/USC-patent-7-18.webp?t=1721342891" type="image/jpeg" medium="image" fileSize="143930">
        <media:title type="plain">“Thin film endovascular electrode array and method of fabrication.”</media:title>
        <media:description type="plain">US20240215889-A1, “Thin film endovascular electrode array and method of fabrication.”
Assignee: University of Southern California
Inventors: Meng, Ellis; Thielen, Brianna Leilani
IPC codes: A61B 5/00; A61B 5/263
Publication date: July 4, 2024
Earliest priority details: US2022436301, Dec. 30, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers develop brain implant for neural recording, stimulation</title>
      <description>Researchers from Arizona State University and Mayo Clinic have filed for protection of wireless, battery-free brain implants which may be used in the monitoring, stimulation, and treatment of epilepsy, tumors, neurodegenerative disorders, neuroinflammatory conditions and trauma.</description>
      <content:encoded>
        <![CDATA[Researchers from Arizona State University and Mayo Clinic have filed for protection of wireless, battery-free brain implants which may be used in the monitoring, stimulation, and treatment of epilepsy, tumors, neurodegenerative disorders, neuroinflammatory conditions and trauma.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/709985</guid>
      <pubDate>Thu, 11 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709985-researchers-develop-brain-implant-for-neural-recording-stimulation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/wireless-brain-implant-11july24.webp?t=1720733432" type="image/jpeg" medium="image" fileSize="244931">
        <media:title type="plain">wireless brain implant</media:title>
        <media:description type="plain">WO2024119097-A1, “Brain implant devices and methods.”Assignee: Mayo Foundation for Medical Education and Research; Arizona State UniversityInventors: Benbuk, Ahmed Abed; Christen, Jennifer Blain; Gulick, Daniel; Liu, Shiyi; Moniz Garcia, Diogo P.; Quinones-Hinojosa, AlfredoIPC Codes: A61N 1/36; A61N 1/05; A61N 1/375Publication date: June 6, 2024Earliest priority details: US2022429539, Dec. 1, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Belle.ai patents AI platform for evaluating, tracking skin conditions</title>
      <description>A little over two months after the granting of its very first patent which described computer-based systems for diagnosing psoriasis, Belletorus Corp. welcomed the publication of two continuation-in-part child filings on similar such systems for the diagnosis of eczema and determining the severity of skin diseases such as psoriasis, eczema and skin cancer.</description>
      <content:encoded>
        <![CDATA[A little over two months after the granting of its very first patent which described computer-based systems for diagnosing psoriasis, Belletorus Corp. welcomed the publication of two continuation-in-part child filings on similar such systems for the diagnosis of eczema and determining the severity of skin diseases such as psoriasis, eczema and skin cancer.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/708733</guid>
      <pubDate>Wed, 29 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708733-belleai-patents-ai-platform-for-evaluating-tracking-skin-conditions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/belle-ai-skin-29may24.webp?t=1717021433" type="image/jpeg" medium="image" fileSize="153918">
        <media:title type="plain">belle ai skin</media:title>
        <media:description type="plain">US20240135533-A1, “Compute system with eczema diagnostic mechanism and method of operation thereof.”Assignee: Belletorus CorporationInventors: Nguyen, Tien Dung; Nguyen, Thi Thu Hang; Fricker, Paul; Gazeau, Léa Mathilde; Gloss, Matthew Gregory; Hustache-Marmou, Thomas; Mariwalla, Kavita; McAnelly, Emily Kathryn; Morbitzer, Megan M.; Nguyen, Duong Thuy; Nguyen, Hoang-Phuong; Nguyen, Nga Thi Thuy; Nguyen, Thang Duc; Perlis, Clifford; Szajna, Christopher C.; Wolfe, JonathanIPC codes: G06T 7/00; G06T 7/136Publication date: Apr. 24, 2024Earliest priority details: US2022893632, Aug. 23, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers develop origami-like device for heart monitoring</title>
      <description>Wubin Bai, assistant professor of applied physical sciences at UNC-Chapel Hill, is seeking protection for morphable 3D-folded microelectronic mesostructures, including epicardial bioelectronic probes, made using concepts borrowed from origami.</description>
      <content:encoded>
        <![CDATA[Wubin Bai, assistant professor of applied physical sciences at UNC-Chapel Hill, is seeking protection for morphable 3D-folded microelectronic mesostructures, including epicardial bioelectronic probes, made using concepts borrowed from origami.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/708284</guid>
      <pubDate>Fri, 17 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708284-researchers-develop-origami-like-device-for-heart-monitoring</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/oragami-heart-monitor-17may24.webp?t=1715984895" type="image/jpeg" medium="image" fileSize="226820">
        <media:title type="plain">oragami-heart-monitor</media:title>
        <media:description type="plain">WO2024086654-A1, “Apparatuses, methods, and systems for reconfigurable three-dimensional mesostructures.”Assignee: The University Of North Carolina At Chapel HillInventors: Bai, Wubin; Zhang, LinIPC Codes: A61B 5/283; A61B 5/00Publication date: April 24, 2024Earliest priority details: US2022380355, Oct. 20, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Masimo’s Stork takes flight with FDA’s over-the-counter clearance</title>
      <description>Masimo Corp.’s pride and joy, the Stork baby monitor, achieved a new developmental milestone with U.S. FDA clearance for over-the-counter marketing. The agency cleared Stork, which monitors key vital signs including oxygen saturation level, pulse rate and skin temperature, for use on a prescription basis in December. It has been available in the U.S. as a health and wellness device since August 2023.</description>
      <content:encoded>
        <![CDATA[Masimo Corp.’s pride and joy, the Stork baby monitor, achieved a new developmental milestone with U.S. FDA clearance for over-the-counter marketing. The agency cleared Stork, which monitors key vital signs including oxygen saturation level, pulse rate and skin temperature, for use on a prescription basis in December. It has been available in the U.S. as a health and wellness device since August 2023.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/708043</guid>
      <pubDate>Mon, 06 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708043-masimos-stork-takes-flight-with-fdas-over-the-counter-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Masimo-Stork-6may24.webp?t=1715085330" type="image/jpeg" medium="image" fileSize="82177">
        <media:title type="plain">Masimo Stork</media:title>
        <media:description type="plain">Masimo Stork baby monitor. Credit: Masimo Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Patent filed for AI use in early detection of neonatal brain injuries</title>
      <description>In what represents its first patenting, PBSF Inc. filed for protection of brain monitoring and neuroprotection strategies for infants at high risk on a large scale.</description>
      <content:encoded>
        <![CDATA[In what represents its first patenting, PBSF Inc. filed for protection of brain monitoring and neuroprotection strategies for infants at high risk on a large scale.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/707914</guid>
      <pubDate>Tue, 30 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707914-patent-filed-for-ai-use-in-early-detection-of-neonatal-brain-injuries</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/ai-tbi.webp?t=1714514939" type="image/png" medium="image" fileSize="75362">
        <media:title type="plain">ai-tbi</media:title>
        <media:description type="plain">WO2024074874-A1, “Time-series anomaly detection for health care.”Assignee: PBSF Inc.Inventors: Variane, GabrielIPC Codes: G16H 50/20; G16H 50/50; A61B 5/00Publication date: April 11, 2024Earliest priority details: WO2022IB59579, Oct. 6, 2024</media:description>
      </media:content>
    </item>
    <item>
      <title>Paindrainer patents digital therapeutic pain management app</title>
      <description>Lund, Sweden based-Paindrainer AB received notification from the European Patent Office that it intends to grant this patent application for its digital tool, Paindrainer, which coaches users in managing their pain and provides guidance on how to reach a personalized activity balance to reach an optimal functional level and alleviate pain.</description>
      <content:encoded>
        <![CDATA[Lund, Sweden based-Paindrainer AB received notification from the European Patent Office that it intends to grant this patent application for its digital tool, Paindrainer, which coaches users in managing their pain and provides guidance on how to reach a personalized activity balance to reach an optimal functional level and alleviate pain.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/707903</guid>
      <pubDate>Mon, 29 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707903-paindrainer-patents-digital-therapeutic-pain-management-app</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/paindrainer-29apr-24.webp?t=1714430294" type="image/jpeg" medium="image" fileSize="165201">
        <media:title type="plain">Paindrainer</media:title>
        <media:description type="plain">EP4186064-A1, “A pain management system.”Assignee: Paindrainer ABInventors: Borrebaeck, Carl, Arne, Krister; Klement, Maria, Linnea, Elisabeth, Rosén; Barkfors, Mats, GöranIPC Codes: A61B 5/021; A61B 5/00; G06N 3/08; G16H 10/60; A61B 5/024; G16H 20/00; A61B 5/01; A61B 5/11; G06N 3/04; G16H 10/20; G16H 50/30Publication date: May 31, 2023 (also published as: WO2022018300A1, Jan. 27; US20230268075-A1, Aug. 24, 2023; CA3186801-A1, Jan. 27, 2022; JP2023535741-A, Aug. 21, 2023; and, KR2023095915-A, Jun. 6, 2023)Earliest priority details: GB202011500, July 24, 2020</media:description>
      </media:content>
    </item>
    <item>
      <title>Anjo.ai develops wearable that uses AI to detect allergic reactions</title>
      <description>In what represents its first patenting, Anjo.ai Inc seeks protection of systems for remote monitoring, early detection and notification for life-threatening allergic anaphylactic reactions using wearable sensors and artificial intelligence. The system can recognize an allergic reaction even before the visible symptoms appear.</description>
      <content:encoded>
        <![CDATA[In what represents its first patenting, Anjo.ai Inc seeks protection of systems for remote monitoring, early detection and notification for life-threatening allergic anaphylactic reactions using wearable sensors and artificial intelligence. The system can recognize an allergic reaction even before the visible symptoms appear.
]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/706894</guid>
      <pubDate>Mon, 01 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706894-anjoai-develops-wearable-that-uses-ai-to-detect-allergic-reactions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Patent Highlights/anjo-ai.webp?t=1712000127" type="image/jpeg" medium="image" fileSize="154671">
        <media:title type="plain">anjo-ai</media:title>
        <media:description type="plain">WO2024047640-A1, “System and method for allergic reaction detection.”Assignee: Anjo.ai Inc.Inventors: Golan, Tal; Lior, Matan; Nocham, ItamarIPC Codes: A61B 5/024; A61B 5/02; A61B 5/00Publication date: Mar. 7, 2024Earliest priority details: US2022401738, Aug. 29, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>RDS receives CE mark for remote monitoring device, plans series A</title>
      <description>Rhythm Diagnostic Systems SA received CE mark approval from EU authorities for Multisense, a wearable device that continuously monitors patients remotely. The company looks to market the device first in France and Germany.</description>
      <content:encoded>
        <![CDATA[Rhythm Diagnostic Systems SA received CE mark approval from EU authorities for Multisense, a wearable device that continuously monitors patients remotely. The company looks to market the device first in France and Germany.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/705984</guid>
      <pubDate>Tue, 05 Mar 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705984-rds-receives-ce-mark-for-remote-monitoring-device-plans-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/RDS-Multisense-5mar24.webp?t=1709675602" type="image/jpeg" medium="image" fileSize="154976">
        <media:title type="plain">RDS Multisense</media:title>
        <media:description type="plain">The Rhythm Diagnostic Systems SA Multisense wearable device remotely monitors heart rate, respiratory rate, oxygen saturation, skin temperature, activity level, and body posture in real-time. Credit: RDS SA</media:description>
      </media:content>
    </item>
    <item>
      <title>Bambi Belt develops defibrillator-proof neonate vital sign monitoring belt</title>
      <description>Through its intellectual property holding company, Eindhoven, the Netherlands-based Bambi Medical BV is seeking patent protection for an enhancement to its flexible sensor belt that is worn around the abdomen for monitoring the vital signs of neonates.</description>
      <content:encoded>
        <![CDATA[Through its intellectual property holding company, Eindhoven, the Netherlands-based Bambi Medical BV is seeking patent protection for an enhancement to its flexible sensor belt that is worn around the abdomen for monitoring the vital signs of neonates.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/705443</guid>
      <pubDate>Wed, 21 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705443-bambi-belt-develops-defibrillator-proof-neonate-vital-sign-monitoring-belt</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/bambi-belt-21feb24.webp?t=1708550773" type="image/jpeg" medium="image" fileSize="155416">
        <media:title type="plain">Bambi Belt</media:title>
        <media:description type="plain">WO2024025416-A1, “Baby vital sign monitoring belt.”Assignee: Bambi Belt Holding BVInventors: Caparelli, Claudia; Visvanathan, Karthikeyan; Wierts, Aron; Wingelaar, Paul Jan HubertusIPC Codes: A61B 5/282; A61B 5/00Publication date: Feb. 1, 2024Earliest priority details: NL20222032605, July 26, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Acorai raises $4.5M in seed for heart monitor trial</title>
      <description>The $4.5 million in seed funding that Acorai AB recently raised will allow the company to continue its forward momentum in developing its technology to support the treatment of patients living with heart failure, Matthew Mace, co-founder and chief scientific officer told BioWorld. In practice, this means that with the funds the company will be able to meet its “projected timelines on the path toward regulatory approval in the U.S., focus on market entry and get the device into the hands of health care professionals sooner.”</description>
      <content:encoded>
        <![CDATA[The $4.5 million in seed funding that Acorai AB recently raised will allow the company to continue its forward momentum in developing its technology to support the treatment of patients living with heart failure, Matthew Mace, co-founder and chief scientific officer told <em>BioWorld</em>. In practice, this means that with the funds the company will be able to meet its “projected timelines on the path toward regulatory approval in the U.S., focus on market entry and get the device into the hands of health care professionals sooner.”]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/704742</guid>
      <pubDate>Fri, 26 Jan 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704742-acorai-raises-45m-in-seed-for-heart-monitor-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Acorai-Heart-Monitor-16aug23.webp?t=1692216157" type="image/jpeg" medium="image" fileSize="137982">
        <media:title type="plain">Acorai Heart Monitor</media:title>
        <media:description type="plain">The Acorai Heart Monitor can track vital measurements in patients with Stage C heart failure who have been referred for hemodynamic monitoring. Credit: Acroai</media:description>
      </media:content>
    </item>
    <item>
      <title>Vectorious improves accuracy of heart pressure monitoring implants</title>
      <description>Vectorious Medical Technologies Ltd. is seeking patent protection for a method for predicting the occurrence of a heart condition by receiving a multiple measurements of blood pressure acquired in a patient’s heart.</description>
      <content:encoded>
        <![CDATA[Vectorious Medical Technologies Ltd. is seeking patent protection for a method for predicting the occurrence of a heart condition by receiving a multiple measurements of blood pressure acquired in a patient’s heart.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/703774</guid>
      <pubDate>Fri, 22 Dec 2023 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703774-vectorious-improves-accuracy-of-heart-pressure-monitoring-implants</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Patent highlights/vectorious-hrm-implant-22dec23.webp?t=1703273538" type="image/jpeg" medium="image" fileSize="93587">
        <media:title type="plain">vectorious hrm implant</media:title>
        <media:description type="plain">WO2023238061-A1, “Predicting and managing congestive heart failure based on blood pressure measurements received from an implanted device.”Assignee: Vectorious Medical Technologies Ltd.Inventors: Handelman, Maoz; Hershko, Matan; Marianer, Tom; Orion, Eyal; Rabinowicz, AlonIPC Codes: A61B 5/0215; A61B 5/00; A61B 5/11; A61B 5/021Publication date: Dec. 14, 2023Earliest priority details: US2022350439, June 9, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Parsortix system unlocking opportunities in melanoma brain metastasis study</title>
      <description>Angle plc’s Parsortix system, which captures and harvest circulating tumor cells (CTCs) for liquid biopsy analysis, has been used in breakthrough work by researchers at the University of New Mexico looking into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that “… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.”</description>
      <content:encoded>
        <![CDATA[Angle plc’s Parsortix system, which captures and harvest circulating tumor cells (CTCs) for liquid biopsy analysis, has been used in breakthrough work by researchers at the University of New Mexico looking into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that “… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.”]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/703518</guid>
      <pubDate>Mon, 11 Dec 2023 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703518-parsortix-system-unlocking-opportunities-in-melanoma-brain-metastasis-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Angles-Parsortix-system-11dec23.webp?t=1702334380" type="image/jpeg" medium="image" fileSize="106309">
        <media:title type="plain">Angles Parsortix system</media:title>
      </media:content>
    </item>
    <item>
      <title>First AID positions Dexcom for healthy new year</title>
      <description>Dexcom Inc. achieved the first integrations of an automated insulin delivery system (AID) approved for use in the U.S. with its G7 continuous glucose monitoring (CGM) integrating with Tandem Diabetes Care Inc.’s T2:slim X2, announced on Dec. 6, and integration with the Ilet Bionic Pancreas made by Beta Bionics Inc. revealed on Dec. 7.</description>
      <content:encoded>
        <![CDATA[Dexcom Inc. achieved the first integrations of an automated insulin delivery system (AID) approved for use in the U.S. with its G7 continuous glucose monitoring (CGM) integrating with Tandem Diabetes Care Inc.’s T2:slim X2, announced on Dec. 6, and integration with the Ilet Bionic Pancreas made by Beta Bionics Inc. revealed on Dec. 7.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/703350</guid>
      <pubDate>Thu, 07 Dec 2023 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703350-first-aid-positions-dexcom-for-healthy-new-year</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Dexcom_G7_Tandem_tslim_X2-7dec23.webp?t=1701988721" type="image/jpeg" medium="image" fileSize="94855">
        <media:title type="plain">Dexcom G7 Tandem tslim X2</media:title>
        <media:description type="plain">Dexcom Corp.’s G7 continuous glucose monitor is integrated with Tandem Diabetes Care Inc.’s T2:slim X2. Credit: Dexcom</media:description>
      </media:content>
    </item>
    <item>
      <title>Omini develops blood testing platform for heart failure</title>
      <description>Omini SA hopes that the multiplexed blood testing platform it is developing will transform the lives of patients suffering from heart failure. With its multiplex, sensor-based testing strip that simultaneously measures four key biomarkers from a single drop of blood, the company’s technology should increase the chance of a patient’s survival and reduce pressure on health care systems, Joanne Kanaan, CEO and co-founder of Omini, told BioWorld.</description>
      <content:encoded>
        <![CDATA[Omini SA hopes that the multiplexed blood testing platform it is developing will transform the lives of patients suffering from heart failure. With its multiplex, sensor-based testing strip that simultaneously measures four key biomarkers from a single drop of blood, the company’s technology should increase the chance of a patient’s survival and reduce pressure on health care systems, Joanne Kanaan, CEO and co-founder of Omini, told <em>BioWorld</em>.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/703348</guid>
      <pubDate>Thu, 07 Dec 2023 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703348-omini-develops-blood-testing-platform-for-heart-failure</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Jeremy-Barande-Ecole-Polytechnique-7dec23.webp?t=1701988723" type="image/jpeg" medium="image" fileSize="124202">
        <media:title type="plain">Jeremy Barande Ecole Polytechnique</media:title>
        <media:description type="plain">The Omni blood testing platform can measure four blood biomarkers. Credit: Omini sensors/Jérémy Barande/Ecole Polytechnique</media:description>
      </media:content>
    </item>
    <item>
      <title>Brainspec AI FDA cleared for noninvasive brain chemistry analysis</title>
      <description>Brainspec Inc. received U.S. FDA 510(k) clearance for use of its artificial intelligence platform, Brainspec Core, in noninvasive measurement of brain chemistry using magnetic resonance spectroscopy (MRS).</description>
      <content:encoded>
        <![CDATA[Brainspec Inc. received U.S. FDA 510(k) clearance for use of its artificial intelligence platform, Brainspec Core, in noninvasive measurement of brain chemistry using magnetic resonance spectroscopy (MRS).]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/703190</guid>
      <pubDate>Wed, 29 Nov 2023 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703190-brainspec-ai-fda-cleared-for-noninvasive-brain-chemistry-analysis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/BrainSpec_3-29nov23.webp?t=1701299278" type="image/jpeg" medium="image" fileSize="102371">
        <media:title type="plain">BrainSpec</media:title>
        <media:description type="plain">Brainspec Core received U.S. FDA 510(k) clearance. Credit: Brainspec Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Glucometrics, G2E to co-develop smart insulin pen with novel API</title>
      <description>Glucometrics Co. Ltd. is rolling out its self-developed application programming interface (API) for diabetes care in steps, and the latest partnership with G2E Co. Ltd. is underway to develop a smart insulin pen loaded with the interface.</description>
      <content:encoded>
        <![CDATA[Glucometrics Co. Ltd. is rolling out its self-developed application programming interface (API) for diabetes care in steps, and the latest partnership with G2E Co. Ltd. is underway to develop a smart insulin pen loaded with the interface.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/702254</guid>
      <pubDate>Fri, 10 Nov 2023 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/702254-glucometrics-g2e-to-co-develop-smart-insulin-pen-with-novel-api</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/dia-conn-platform.webp?t=1699653522" type="image/jpeg" medium="image" fileSize="118328">
        <media:title type="plain">DiaConn Platform</media:title>
        <media:description type="plain">Part of the Dia:Conn ecosystem, the G8-plus smart insulin pen promises to supply advanced decision supporting features. Credit: Courtesy Diaconn</media:description>
      </media:content>
    </item>
    <item>
      <title>GE Healthcare tackles alarm fatigue with Portrait Mobile</title>
      <description>The largest strike by U.S. health care workers, in early Oct. 2022, brought increased attention to the seriousness of the staff shortage in hospitals and the urgent need to address it. Multiple reports over the last 10 years have documented the impact of alarm fatigue on nurses, in particular, and its contribution to professional burnout and ongoing staffing issues. A bit counterintuitively, more integrated, continuous monitoring of vital signs reduces alarm fatigue for medical staff attending to post-surgical patients, a study by GE Healthcare Technologies Inc. and Cleveland Clinic found.</description>
      <content:encoded>
        <![CDATA[<p>The largest strike by U.S. health care workers, in early Oct. 2022, brought increased attention to the seriousness of the staff shortage in hospitals and the urgent need to address it. Multiple reports over the last 10 years have documented the impact of alarm fatigue on nurses, in particular, and its contribution to professional burnout and ongoing staffing issues. A bit counterintuitively, more integrated, continuous monitoring of vital signs reduces alarm fatigue for medical staff attending to post-surgical patients, a study by GE Healthcare Technologies Inc. and Cleveland Clinic found.</p><br>]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/701778</guid>
      <pubDate>Mon, 16 Oct 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701778-ge-healthcare-tackles-alarm-fatigue-with-portrait-mobile</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Portrait-mobile-family-16oct23.webp?t=1697492886" type="image/jpeg" medium="image" fileSize="87984">
        <media:title type="plain">Portrait mobile family</media:title>
        <media:description type="plain">GE Healthcare Portrait Mobile Monitoring Solution (COSMOS). Credit: GE Healthcare</media:description>
      </media:content>
    </item>
    <item>
      <title>Patent update: Medwatch’s first patent describes its blood glucose monitoring wearable</title>
      <description>Medwatch Technologies Inc. reported a patent for the use of near infrared (NIR) spectroscopy, from collection of NIR LEDs surrounding a photo diode sensitive to wavelengths in the range 400 nm to 1650 nm, to noninvasively detect blood glucose concentrations, in a multi-sensing wearable device such as a watch or patch.</description>
      <content:encoded>
        <![CDATA[Medwatch Technologies Inc. reported a patent for the use of near infrared (NIR) spectroscopy, from collection of NIR LEDs surrounding a photo diode sensitive to wavelengths in the range 400 nm to 1650 nm, to noninvasively detect blood glucose concentrations, in a multi-sensing wearable device such as a watch or patch.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/700948</guid>
      <pubDate>Mon, 18 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700948-patent-update-medwatchs-first-patent-describes-its-blood-glucose-monitoring-wearable</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Patent highlights/medwatch-tech-blood-glucose-monitor-18sept23.webp?t=1695073219" type="image/jpeg" medium="image" fileSize="150188">
        <media:title type="plain">medwatch tech blood glucose monitor</media:title>
        <media:description type="plain">WO2023168127-A2, “Blood glucose estimation using near infrared light emitting diodes.”
Assignee: Medwatch Technologies Inc
Inventors: Matichuk, Bruce; Moore, Mike E.
IPC Codes: G16H 10/40; A61B 5/145
Publication date: Sep. 7, 2023
Earliest priority details: US2022316901, Mar. 4, 2022</media:description>
      </media:content>
    </item>
    <item>
      <title>Nemaura raises $6.5M, eyes Saudi diabetes market</title>
      <description>Nemaura Medical Inc. recently raised $6.5 million in non-dilutive funding through a clean debt facility with no warrants or convertible elements. The funding came from its existing lender and is expected to fund Nemaura’s ongoing efforts to commercialize its daily disposable, wearable glucose sensors.</description>
      <content:encoded>
        <![CDATA[Nemaura Medical Inc. recently raised $6.5 million in non-dilutive funding through a clean debt facility with no warrants or convertible elements. The funding came from its existing lender and is expected to fund Nemaura’s ongoing efforts to commercialize its daily disposable, wearable glucose sensors.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/700747</guid>
      <pubDate>Fri, 08 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700747-nemaura-raises-65m-eyes-saudi-diabetes-market</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Financial-graph.webp?t=1683744280" type="image/jpeg" medium="image" fileSize="275653">
        <media:title type="plain">Financial graph</media:title>
      </media:content>
    </item>
    <item>
      <title>Patent update: Wearoptimo plans further protection for its microwearable health sensors</title>
      <description>Wearoptimo Pty. Ltd. saw the publication of a patent application for its method and system for analyzing measurements from a wearable patch with sensors connected to microstructures that when applied to the skin penetrate the stratum corneum and enter the viable epidermis.</description>
      <content:encoded>
        <![CDATA[<p>Wearoptimo Pty. Ltd. saw the publication of a patent application for its method and system for analyzing measurements from a wearable patch with sensors connected to microstructures that when applied to the skin penetrate the stratum corneum and enter the viable epidermis.</p>]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/700746</guid>
      <pubDate>Fri, 08 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700746-patent-update-wearoptimo-plans-further-protection-for-its-microwearable-health-sensors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Patent highlights/wearoptimo-microwearable-8sept23.webp?t=1694201893" type="image/jpeg" medium="image" fileSize="228876">
        <media:title type="plain">Wearoptimo microwearable sensor</media:title>
        <media:description type="plain">WO2023159271-A1, “Measurement analysis.”Assignee: Wearoptimo Pty. Ltd.Inventors: Aburn, Matthew James; Brewer, Anthony Mark; Jones, Jeremy Gwyn Upham; Mateen, FarrukhIPC codes: A61B 5/1486; G05B 23/02; G01N 33/487; G06F 18/15; B81B 7/04; A61N 1/40; G06F 18/2135; G01N 33/483; G01N 33/50; A61B 5/00; G16H 50/50; B81B 7/02; G06N 5/04; G01N 27/02; A61B 5/053; A61N 1/05Publication date: Aug. 31, 2023Earliest priority details: AU2022900429, Feb. 24, 2022</media:description>
      </media:content>
    </item>
  </channel>
</rss>
